Table 4.
Sensitivity analyses: risk of serious infections by using different PSs
| csDMARDs | TNFis | Non‐TNFi bDMARDs | |
|---|---|---|---|
| PS in quintiles | |||
| Adjusted HR (95% CI) for PS only | Reference | 1.06 (0.87‐1.28) | 1.22 (0.92‐1.62) |
| Adjusted HR (95% CI) for PS and time‐varying confounders | Reference | 1.33 (1.06‐1.70) | 1.53 (1.05‐2.23) |
| PS continuous: Non‐TNFi bDMARDs vs TNFis | |||
| Adjusted HR (95% CI) for PS only | … | Reference | 1.14 (0.88‐1.46) |
| Adjusted HR (95% CI) for PS and time‐varying confounders | … | Reference | 1.13 (0.85‐1.50) |
| PS without the No. of prior bDMARDs | |||
| Adjusted HR (95% CI) for PS only | Reference | 1.11 (0.92‐1.35) | 1.21 (0.92‐1.59) |
| Adjusted HR (95% CI) for PS and time‐varying confounders | Reference | 1.39 (1.10‐1.75) | 1.55 (1.07‐2.25) |
Abbreviation: bDMARD, biological disease‐modifying antirheumatic drug; CI, confidence interval; csDMARD, conventional synthetic disease‐modifying antirheumatic drug; HR, hazard ratio; PS, propensity score; TNFi, tumor necrosis factor α inhibitor; WCE, weighted cumulative exposure.